Utama › Sklerosis Pelbagai › Pennsylvania
Kajian klinikal Sklerosis Pelbagai di Pennsylvania
7 kajian untuk Sklerosis Pelbagai sedang mencari peserta di lokasi di Pennsylvania.
Bandar di Pennsylvania
Teks kajian rasmi (Bahasa Inggeris)
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Thomas Jefferson University, Jefferson Headache Center, Philadelphia
Mengambil pesertaFasa 2
Umur 18 hingga 70 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06782490Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- UPMC Hillman Cancer Center, Pittsburgh
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT03816345A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- TG Therapeutics Investigational Trial Site, Bethlehem
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT06433752RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- University of Pennsylvania, Philadelphia
Mengambil pesertaFasa 2
Umur 18 hingga 80 · Semua jantina · Dikemas kini 15 Sep 2026 · NCT07002034Genes and Environment in Multiple Sclerosis
- University of Pittsburgh, Pittsburgh
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Mei 2026 · NCT01353547Central Vein Sign in Multiple Sclerosis Extension Study
- University of Pennsylvania, Philadelphia
Mengambil peserta
Umur 18 hingga 65 · Semua jantina · Dikemas kini 20 Feb 2026 · NCT07424027Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
- University of Pittsburgh, Pittsburgh
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 7 ke atas · Semua jantina · Dikemas kini 29 Dis 2025 · NCT02994121Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.